We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Transesophageal Device Helps Assess Cardiac Performance

By HospiMedica International staff writers
Posted on 15 May 2012
An advanced hemodynamic transesophageal echocardiographic (TEE) management probe enables physicians to identify the underlying cause of hemodynamic instability in patients with trauma or septic shock.

The ClariTEE indwelling TEE probe is intended for use in long-term clinical settings, allowing physicians to directly visualize cardiac size and function in high-risk anesthesiology patients during and after surgery. More...
The disposable probe is the size of a nasogastric tube, and uses a high frequency (7 MHz) ultrasound signal for resolution combined with a 15 cm depth of penetration, offering both color flow and B imaging modes. It provides data about cardiac filling pressures, function, and the presence of effusion or tamponade, and by obtaining serial views it can also be used to monitor changes following administration of fluids or inotropic agents.

The flexibility of the probe is based on a bending section, called AdaptaFlex, which enables the distal tip to conform to a variety of anatomical variations, allowing ease of positioning and rapid image acquisition when imaging the trans-gastric short axis view of the left ventricle. While not designed to be a replacement for intra-operative monitoring, the ClariTEE extends the hemodynamic assessment capabilities of TEE from the operating room to the intensive care unit (ICU) in postcardiac surgery patients, and provides new hemodynamic management capabilities in noncardiac surgical patients. The ClariTEE probe is a product of ImaCor (Garden City, NY, USA.

“ClariTEE is the world’s only miniaturized, disposable TEE probe that can lay in-dwelling for 72 hours, which is essential for initial resuscitation and subsequent patient management while medical interventions are made,” said Peter Pellerito, president and CEO of ImaCor. “Seamless integration of ultrasound is the future of critical care.”

A TEE uses a specialized probe containing an ultrasound transducer at its tip that is passed into the patient's esophagus. The advantages over a transthoracic echocardiogram (TTE) include clearer images, especially of structures that are difficult to view transthoracicly. The explanation for this is that the heart rests directly upon the esophagus, leaving only millimeters that the ultrasound beam has to travel. This reduces the attenuation of the ultrasound signal, generating a stronger return signal, thus ultimately enhancing image and Doppler quality.

Related Links:
ImaCor


Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
VTE Prevention System
Flowtron ACS900
Half Apron
Demi
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The fiber in the brain implant is less than half a millimeter thick (Photo courtesy of Peter Aagaard Brixen)

Brain Implant Records Neural Signals and Delivers Precise Medication

Neurological diseases such as epilepsy involve complex interactions across multiple layers of the brain, yet current implants can typically stimulate or record activity from only a single point.... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.